Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | FPR2 | P25090 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27039419 | 1.00 | SCN9A (0.39) | SCN9AFPR2SYKCA12CA1 | |
| SCHEMBL27039418 | 1.00 | SCN9A (0.39) | SCN9AFPR2SYKCA12CA1 | |
| SCHEMBL16873172 | 0.87 | IRAK4 (0.43) | CA12CA1CA2CA9IRAK4 | |
| SCHEMBL31291012 | 0.82 | IRAK4 (0.41) | CA12CA1CA2CA9IRAK4 | |
| SCHEMBL27040163 | 0.82 | IRAK4 (0.41) | CA12CA1CA2CA9IRAK4 | |
| SCHEMBL27040161 | 0.82 | IRAK4 (0.41) | CA12CA1CA2CA9IRAK4 | |
| SCHEMBL12931891 | 0.79 | ATR (0.47) | CA12CA1CA2CA9P2RX3 | |
| SCHEMBL21680693 | 0.76 | SCN9A (0.35) | SCN9AFPR2SYK | |
| SCHEMBL21680695 | 0.76 | SCN9A (0.35) | SCN9AFPR2SYK | |
| SCHEMBL30669758 | 0.76 | SCN9A (0.35) | SCN9AFPR2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735424-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250042906-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025006946-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042906-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK2 | SCN9A 4653/4885FPR2 3618/4885SYK 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.